Canada Pension Plan Investment Board boosted its position in Eli Lilly and Company (NYSE:LLY) by 6.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,306,434 shares of the company’s stock after buying an additional 75,800 shares during the period. Canada Pension Plan Investment Board owned about 0.12% of Eli Lilly and Company worth $109,884,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its position in Eli Lilly and Company by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock valued at $27,280,000 after buying an additional 9,680 shares in the last quarter. Franklin Street Advisors Inc. NC bought a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $320,000. Pictet North America Advisors SA bought a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $8,818,000. Washington Trust Bank boosted its position in shares of Eli Lilly and Company by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock valued at $872,000 after buying an additional 4,990 shares during the period. Finally, Xact Kapitalforvaltning AB acquired a new stake in Eli Lilly and Company during the third quarter valued at about $12,653,000. Institutional investors and hedge funds own 75.44% of the company’s stock.
Shares of Eli Lilly and Company (LLY) traded down 0.21% during trading on Friday, hitting $81.88. 4,903,157 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $80.07 and a 200-day moving average price of $78.80. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The stock has a market cap of $86.49 billion, a P/E ratio of 39.59 and a beta of 0.36.
Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Eli Lilly and Company had a net margin of 10.13% and a return on equity of 26.64%. The business had revenue of $5.23 billion during the quarter, compared to analysts’ expectations of $5.22 billion. During the same period last year, the business earned $0.83 earnings per share. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. Equities research analysts expect that Eli Lilly and Company will post $4.12 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 9th. Stockholders of record on Monday, May 15th were paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend was Thursday, May 11th. Eli Lilly and Company’s payout ratio is 100.48%.
A number of equities analysts have recently weighed in on the company. BidaskClub upgraded Eli Lilly and Company from a “sell” rating to a “hold” rating in a research note on Wednesday. Jefferies Group LLC reaffirmed a “buy” rating and issued a $97.00 target price (up previously from $95.00) on shares of Eli Lilly and Company in a report on Saturday, March 11th. Citigroup Inc. raised their target price on Eli Lilly and Company from $92.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, April 19th. Morgan Stanley downgraded Eli Lilly and Company from an “overweight” rating to an “equal weight” rating and set a $82.00 price objective on the stock. in a report on Monday, April 17th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $92.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, May 16th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Eli Lilly and Company presently has an average rating of “Hold” and a consensus target price of $87.59.
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $84.67, for a total transaction of $17,780,700.00. Following the sale, the insider now owns 124,690,804 shares of the company’s stock, valued at $10,557,570,374.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and Company stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the transaction, the insider now directly owns 14,041 shares in the company, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders sold 259,733 shares of company stock valued at $21,829,137 in the last quarter. 0.20% of the stock is owned by insiders.
About Eli Lilly and Company
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.